Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours

NCT02338622 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT02338622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02338622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2014
Completion date
March 21, 2017
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer